YAKHAK HOEJI

Table. 2.

Table 2 Signal detection of GLP-1 RAs using disproportionality analysis in WHO-UMC VigiBase^® from April 2005 to January 2023

	Cases of GLP-1 RA	Non-cases of GLP-1 RA	ROR (95% CI)	Signal^†
Biliary tract disorders^*
America	122	158,002	1.29 (1.05-1.59)	O
Europe	91	47,749	0.64 (0.51-0.79)	X
Asia	19	9,019	1.41 (0.89-2.25)	X
Other regions	1	1,552	0.81 (0.11-5.95)	X
Gallbladder-related disorders^*
America	396	157,728	2.34 (2.06-2.66)	O
Europe	195	47,645	5.71 (4.62-7.05)	O
Asia	44	8,994	4.12 (2.98-5.69)	O
Other regions	6	1,547	2.32 (0.99-5.43)	X

Abbreviations: ROR, Reporting Odds Ratio; CI, Confidence Interval; WHO-UMC, World Health Organization-Uppsala Monitoring Centre

*The Adverse Events of interest are defined using Standardized MedDRA Queries (SMQ)

^†Safety signals detection with ROR were assessed as AEs where thresholds of ROR were greater than one.